Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
GLP-1 RA Use Linked to Lower Rates of Hyperkalemia in Type 2 Diabetes
MONDAY, Aug. 12, 2024-- Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate...
Pump Use Linked to Significantly Longer Duration of Breastfeeding
MONDAY, Aug. 12, 2024-- Pump use is associated with longer breastfeeding duration, with the lowest risk for breastfeeding cessation seen for non-Hispanic...
Buprenorphine + Naloxone Safe for Opioid Addiction in Pregnancy
MONDAY, Aug. 12, 2024-- Pregnancies exposed to buprenorphine combined with naloxone have similar or more favorable neonatal and maternal outcomes as those...
Prevalence of Homebound 22 Percent in National Medicare Advantage Plan
MONDAY, Aug. 12, 2024-- In a national Medicare Advantage (MA) plan, the prevalence of homebound is 22 percent, and homebound status is independently...
FDA Approves Yorvipath (palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA)...
Substantial Disparities Seen in Cancer Cases, Deaths Among Men
MONDAY, Aug. 12, 2024 -- There are substantial disparities in cancer cases and deaths among men, which are projected to widen by 2050, according to a study...
More Toddler Screen Time Brings More Tantrums, Study Finds
MONDAY, Aug. 12, 2024 -- Using tablets as 'e-babysitters' for toddlers could lead to more tantrums, which in turn can have harried parents trying to calm a...
Getting Fats From Plants Vs. Animals Boosts Your Life Span
MONDAY, Aug. 12, 2024 -- A study of more than 400,000 people tracked for up to 24 years finds that those who got their dietary fat from plants versus animals...
FDA Says No to MDMA as Therapy for PTSD
MONDAY, Aug. 12, 2024 -- Advocates for the use of the psychedelic drug MDMA (midomafetamine) to treat mental health conditions were delivered a setback on...
Brain Study Shows How Classical Music Lifts Your Mood
MONDAY, Aug. 12, 2024 -- Does listening to classical music make you feel sublime? A new study suggests there might be a scientific reason for that...
Even Moderate Drinking Ups Risk for Brain Bleeds After a Fall
MONDAY, Aug. 12, 2024 -- Drinking can increase a senior’s risk of a brain bleed following a fall, even if they only occasionally imbibe, a new study...
FDA Approves Enzeevu (aflibercept-abzv), a Biosimilar to Eylea
Basel, August 12, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the US Food and Drug...
Lykos Therapeutics Announces Complete Response Letter for Midomafetamine Capsules for PTSD
SAN JOSE, Calif., Aug. 9, 2024 /PRNewswire/ -- Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced that the U.S...
FDA Approves neffy (epinephrine nasal spray) Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and...
FDA Approves Lymphir (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma
CRANFORD, N.J., Aug. 8, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius", "Citius Pharma"), announced today that the U.S. Food and...
FDA Approves Zurnai (nalmefene hydrochloride) Auto-Injector for the Emergency Treatment of Known or Suspected Opioid Overdose
STAMFORD, Conn., August 7, 2024 – Purdue Pharma L.P. (“Purdue”) announced today that the U.S. Food and Drug Administration (FDA) approved the...
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
CELEBRATION, Fla., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company...
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
BOSTON--(BUSINESS WIRE)--Jul. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA)...
Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development
July 26, 2024 -- Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration...
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel(R)) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
THOUSAND OAKS, Calif.--(BUSINESS WIRE) July 17, 2024 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel...
First Patients Enrolled in US Pivotal Study of AI-Based Image Analysis Module for Lung Cancer
SANTA CLARA, Calif., Aug. 9, 2024. Invenio Imaging, a leader in intraoperative fresh tissue imaging and artificial intelligence (AI), announced today the...
WestGene to Advance Clinical Trials Following Dual IND Approvals for World's First EB Virus-Related mRNA Therapeutic Cancer Vaccine
CHENGDU, China, Aug. 8, 2024. WestGene Biopharma is proud to announce that its mRNA therapeutic cancer vaccine, WGc-043, has received dual IND approvals from...
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 8, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and...
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
RAHWAY, N.J.--(BUSINESS WIRE) August 8, 2024 --Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation...
Groundbreaking Nipocalimab Study of Pregnant Individuals at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn Published in The New England Journal of Medicine
SPRING HOUSE, Pa., (August 7, 2024) – Johnson & Johnson today announced the results from the Phase 2 open-label UNITY study of nipocalimab for the...
Browse by news type
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
- Drug Shortages
drugclasses.com Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of drugclasses.com in your inbox.
Disclaimer
This library contains syndicated news articles. These articles have not been peer-reviewed by drugclasses.com, and therefore we cannot guarantee accuracy to the highest ethical standards. Do further research as needed. Consultation with your physician is essential.